Will Merck submit Keytruda and Padcev combo approval application to EMA for muscle-invasive bladder cancer by 2 Oct 2026?
Posted 2026-09-19, stated before the outcome.
Merck develops and markets pharmaceutical products including the oncology drug Keytruda. Padcev is an antibody-drug conjugate developed in collaboration with other firms for urothelial cancers. The European Medicines Agency reviews formal marketing-authorization applications for new indications or drug combinations before any approval decision.
The claim
Merck submits a formal application for regulatory approval of the Keytruda and Padcev combination for perioperative treatment of muscle-invasive bladder cancer to the European Medicines Agency.
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.